Compare URGN & DRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URGN | DRH |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | 35 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 2016 | 2004 |
| Metric | URGN | DRH |
|---|---|---|
| Price | $40.70 | $12.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $60.00 | $13.96 |
| AVG Volume (30 Days) | 579.2K | ★ 2.4M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 2.91% |
| EPS Growth | N/A | ★ 144.44 |
| EPS | N/A | ★ 0.51 |
| Revenue | $1,128,000.00 | ★ $1,120,491,000.00 |
| Revenue This Year | $193.48 | $2.10 |
| Revenue Next Year | $68.06 | $2.34 |
| P/E Ratio | ★ N/A | $24.18 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.86 | $7.48 |
| 52 Week High | $50.81 | $13.79 |
| Indicator | URGN | DRH |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 46.80 |
| Support Level | $40.94 | $11.92 |
| Resistance Level | $44.63 | $12.54 |
| Average True Range (ATR) | 1.63 | 0.25 |
| MACD | -0.23 | 0.02 |
| Stochastic Oscillator | 23.37 | 40.29 |
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The company operates in one reportable segment: The hotel ownership segment, which is comprised of upper upscale and luxury chain scale hotels that offer hotel rooms, food and beverage and other ancillary guest services.